Riggs Asset Management’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Riggs Asset Management’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,000	Closed	-$765	–	414
2023 Q1	$765	Buy	3,000 +1,450	+94%	+$1.31K	﹤0.01%	328
2022 Q4	$1.83K	Buy	1,550 +100	+7%	+$210	﹤0.01%	274
2022 Q3	$3K	Buy	1,450 +450	+45%	+$764	﹤0.01%	279
2022 Q2	$2K	Buy	+1,000	New	+$3.91K	﹤0.01%	277

Riggs Asset Management's PEAR Position: Q2 2023 in Review

Riggs Asset Management sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 3,000 shares — an estimated $765 sold.

Riggs Asset Management first reported a position in PEAR in Q2 2022 and held it in 4 quarters. The position peaked at $3K in Q3 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Riggs Asset Management reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Riggs Asset Management sold 3,000 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $765.
Riggs Asset Management first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q2 2022 and held it in 4 quarters.
Riggs Asset Management's Pear Therapeutics, Inc. Class A Common Stock position peaked at $3K in Q3 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Riggs Asset Management's 13F filing for Q2 2023, filed 21 Jul 2023.